DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Brimonidine (Brimonidine Tartrate Ophthalmic) - Summary

 
 



BRIMONIDINE SUMMARY

BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION

Brimonidine tartrate ophthalmic solution 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use.

Brimonidine tartrate ophthalmic solution is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of Brimonidine tartrate ophthalmic solution diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.


See all Brimonidine indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Brimonidine ( Ophthalmic)

Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease. [2012]
treatment of signs and symptoms of moderate dry eye syndrome... CONCLUSION: 0.18% SH caused a statistically significant improvement in both a

Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. [2011.06]
PURPOSE: To assess the impact of open versus masked adherence monitoring on adherence with topical brimonidine using two different dosing schedules... CONCLUSION: The study findings suggest that adherence measurements are not significantly altered by open adherence monitoring, which may simplify future adherence studies. Adherence with brimonidine eye drops was insufficient for most patients. These results demonstrate the necessity to develop new strategies to improve compliance in glaucoma therapy. (c) 2010 The Authors. Acta Ophthalmologica (c) 2010 Acta Ophthalmologica Scandinavica Foundation.

A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. [2011.04]
PURPOSE: To compare the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma. DESIGN: Randomized, double-masked, multicenter clinical trial... CONCLUSION: Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%. Copyright (c) 2011 Elsevier Inc. All rights reserved.

Effect of a fixed brimonidine-timolol combination on intraocular pressure after phacoemulsification. [2011.02]
PURPOSE: To evaluate the effect of a fixed combination of brimonidine-timolol on intraocular pressure (IOP) after phacoemulsification cataract surgery. SETTING: Department of Ophthalmology, Patras University Hospital, Patras, Greece. DESIGN: Prospective randomized comparative case series... CONCLUSION: The fixed brimonidine-timolol combination effectively reduced IOP 6, 12, and 24 hours after phacoemulsification cataract surgery. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Effect of prophylactic topical brimonidine (0.15%) administration on the development of subconjunctival hemorrhage after intravitreal injection. [2011.02]
PURPOSE: Brimonidine (0.15%), which is used to lower intraocular pressure, is an alpha-2-adrenergic agonist that has vasoconstrictive effects. This study examined whether the administration of brimonidine (0.15%) before intravitreal injection prevents subconjunctival hemorrhage... CONCLUSION: The administration of 0.15% brimonidine before an intravitreal injection decreased the incidence, severity, and size of subconjunctival hemorrhage.

more studies >>

Clinical Trials Related to Brimonidine ( Ophthalmic)

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension [Completed]
This study evaluates the safety and efficacy of brimonidine 0. 2%/timolol 0. 5% fixed combination ophthalmic solution compared with concurrent brimonidine 0. 2% and timolol ophthalmic solutions

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs [Completed]
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.

Aqueous Humor Dynamics and Brimonidine [Not yet recruiting]
Investigate nocturnal effects on aqueous humor dynamics of a clinically used eye pressure

- lowering drug, brimonidine, when given for six weeks.

Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema [Not yet recruiting]
Most patients undergoing cataract surgery suffer from corneal edema after the surgery.

Brimonidine drops are a well known and safe Anti-glaucoma medication. the investigators have made several clinical observations that patients receiving Brimonidine drops had a faster resolution of their corneal edema even if they had normal intra-ocular pressure.

The investigators believe that administering topical Brimonidine to patients with significant post operative corneal edema will hasten the resolution of their corneal edema.

Effect of Brimonidine on Corneal Thickness [Recruiting]
Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors there are only few studies available on the impact brimonidine has on the cornea. The aim of the study is to find out

1. whether topical administration of brimonidine results in interaction with corneal alpha-2 adrenoceptors in terms of an increase in corneal thickness and

2. whether there are any differences between the response corneal epithelium, stroma and endothelium show to alpha-2 adrenoceptor stimulation.

more trials >>


Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014